Vivus shares buoyed by late-stage Evamist data
Shares of Vivus were slightly buoyed by the news that its spray-on menopause therapy performed well in a late-stage trial. The Evamist therapy reduced hot flashes by 78 percent compared to women taking a placebo spray. Vivus is planning a marketing application later this year.
- here's the AP report on Evamist
Comments